live sessions
MST:
Mountain Standard Time
MST
:
Mountain Standard Time
Tuesday (February 24) Sessions
Live Now:
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Tuesday
Nicolas Chomont
Université de Montréal, Montreal, Canada
8:35 AM8:35 AM
24 - GLP-1 Receptor Agonists: Are They a Cure for Everything?
Todd T. Brown
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
9:05 AM9:05 AM
25 - Syphilis and Superbugs: Sexually Transmitted Infections in the Era of HIV Control
Jeanne Marrazzo
Infectious Diseases Society of America, Arlington, VA, USA
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
HIV Reservoirs and Cure Strategies
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
133 - A Posttranscriptional Block Limits HIV Env Expression in Reactivated Cells From PWH on ART
Jonathan Richard
Centre de Recherche du CHUM, Montreal, Canada
10:13 AM10:13 AM
134 - Altered Viral Kinetics at ATI After Dual LS-bNAbs Plus ART: A Preliminary Analysis of RIO Arm B
Julia Edgar
University of Oxford, Oxford, UK
10:21 AM10:21 AM
135 - Autologous Neutralising Antibodies and Effective CD8 T Cells Maintain HIV Postintervention Control
Katie Fisher
Aarhus University, Aarhus, Denmark
10:29 AM10:29 AM
136 - Bacteria-Specific CD4+ T Cells Contribute to HIV Persistence During ART
Armando Espinosa Ortiz
Université de Montréal, Montreal, Canada
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
137 - CD4-Targeted IL-15 Enhanced bNAb Activity and Improved SHIV Control After Treatment Interruption
Jeffrey Murry
Gilead Sciences, Inc, Foster City, CA, USA
11:13 AM11:13 AM
138 - Decoding the Somatic Mutation Landscape in Persisting HIV-1-Infected CD4+ T Clones
Marie Armani-Tourret
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:21 AM11:21 AM
139 - Ibalizumab-Targeted Delivery of Tat mRNA Transactivates Provirus Expression In Vivo
Edward F. Kreider
University of Pennsylvania, Philadelphia, PA, USA
11:29 AM11:29 AM
140 - Immune-Mediated Viral Control With Budigalimab ± Trosunilimab: First Results of Phase II Global RCT
Ana Gabriela Pires Dos Santos
AbbVie, Inc, North Chicago, IL, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Three Battles - One Stage: TB, Hepatitis, and Hepatocellular Cancer
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
141 - Efficacy and Safety of BLV 2 or 10 mg in CHD Including Patients With HIV/HBV: MYR301 Final Results
David Wyles
Denver Health Medical Center, Denver, CO, USA
10:13 AM10:13 AM
142 - Hepatitis B Reactivation/Infection in People With HIV on Tenofovir-Sparing Antiretroviral Therapy
Grace Haser
University of California San Francisco, San Francisco, CA, USA
10:21 AM10:21 AM
143 - Long-Term Outcomes of Liver Transplant Recipients Living With HIV: A Multicenter Case-Control Study
José M. Miró
Hospital Clinic of Barcelona, Barcelona, Spain
10:29 AM10:29 AM
144 - Early Detection of HCC via Active Surveillance in Persons With HIV in Uganda at High Risk
Katuku Jim Aizire
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
145 - One-Month Versus 3-Month Rifapentine-Based Tuberculosis Preventive Therapy in People With HIV
Anchalee Avihingsanon
Thai Red Cross AIDS Research Centre, Bangkok, Thailand
11:13 AM11:13 AM
146 - Twice-Daily Dolutegravir With a 4-Month Rifapentine-Based Regimen for HIV-Associated Tuberculosis
Sean Wasserman
St George's University of London, London, UK
11:21 AM11:21 AM
147 - DOLPHIN-Moms: Pharmacokinetics and HIV Suppression With Once-Daily Dolutegravir and 3HP in Pregnancy
Jyoti S. Mathad
Weill Cornell Medicine, New York, NY, USA
11:29 AM11:29 AM
148 - Safety and Treatment Completion of 1HP Versus 3HP in People With HIV: The One-to-Three Trial
Jayajothi Moodley
The Aurum Institute, Johannesburg, South Africa
11:37 AM11:37 AM
149 - Novel Linezolid Dosing With Bedaquiline, Delamanid, and Clofazimine for Drug-Resistant TB Treatment
Constance A. Benson
University of California San Diego, La Jolla, CA, USA
11:45 AM11:45 AM
Questions and Answers (Part 2)
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Next-Generation HIV Strategies for Children and Adolescents: Breakthroughs in Pediatric HIV Prevention, Treatment, and Care
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
150 - DOLPHIN-KIDS: Phase I/II Trial of Dolutegravir With 3HP for TB Prevention in Children With HIV
Nicole Salazar-Austin
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:13 AM10:13 AM
151 - Empiric Valganciclovir Reduces Mortality in Infants Living With HIV and Severe Pneumonia
Pablo Rojo
Fundación para la Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain
10:21 AM10:21 AM
152 - Viral Control Among Children in Botswana Receiving Combination Broadly Neutralizing Antibodies
Gbolahan Ajibola
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
10:29 AM10:29 AM
153 - Very Early ART Initiation Associated With Sustained Aviremia in Time-to-Rebound Pediatric ATI
Gabriela Z. L. Cromhout
University of KwaZulu-Natal, Durban, South Africa
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
154 - DTG/3TC Is Noninferior to DTG-Based 3-Drug ART in Children With HIV: D3/Penta 21 Week-96 Results
Anna Turkova
MRC Clinical Trials Unit at UCL, London, UK
11:13 AM11:13 AM
155 - Long-Acting Cabotegravir+Rilpivirine in Adolescents: IMPAACT 2017 Week 96 & End-of-Study Results
Aditya Gaur
St Jude Children's Research Hospital, Memphis, TN, USA
11:21 AM11:21 AM
156 - Improved Viral Suppression and Retention: Randomized Trial of an Adolescent Transition Intervention
Brian Zanoni
Emory University, Atlanta, GA, USA
11:29 AM11:29 AM
157 - Immunogenicity of 2- Versus 3-Dose HPV Vaccination by HIV Infection Status in Eswatini
Harriet Nuwagaba-Biribonwoha
ICAP at Columbia University, New York, NY, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
We Thought You'd Never Ask: Improving HIV Screening and Testing
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
158 - Cluster-Randomized Stepped-Wedge Trial of HIV Rapid Testing and Risk Assessment in Primary Care
Maria Jesus Perez Elias
Ramon y Cajal Hospital, Madrid, Spain
10:13 AM10:13 AM
159 - Enhanced Opt-Out HIV Screening & Linkage to Care for 216K Patients at 13 Community Health Centers
Timothy Long MD
Health Choice Network, Miami, FL, USA
10:21 AM10:21 AM
160 - Electronic Health Record-Driven Universal HIV Screening and Missed Opportunities in Southeastern US
David E. Hudon
Prisma Health, Greenville, SC, USA
10:29 AM10:29 AM
161 - Using Machine Learning to Optimize HIV Risk Prediction and Case Identification in Eastern Kenya
Peter Kyalo
Center for International Health, Education and Biosecurity (CIHEB) Kenya, Nairobi, Kenya
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
162 - Global Analysis of HIV Oral PrEP-to-Need Ratios (PnR) in 2025
Andrew Hill
University of Liverpool, Liverpool, UK
11:13 AM11:13 AM
163 - The Impact of SEARCH Community Precision Health on HIV Incidence in Rural Kenya and Uganda
Gabriel Chamie
University of California San Francisco, San Francisco, CA, USA
11:21 AM11:21 AM
164 - Urine Tenofovir and POC Viral Load Testing After ART Start: Week 72 Outcomes of STREAM-HIV Trial
Paul K. Drain
University of Washington, Seattle, WA, USA
11:29 AM11:29 AM
165 - Evaluating the Viability of Self-Collected Blood for Remotely Testing HIV Suppression Among MSM
Jeffrey Johnson
Centers for Disease Control and Prevention, Atlanta, GA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Targeting the HIV Reservoir: Novel Cure Strategies
1:30 PM1:30 PM
Session Overview
Marina Caskey
The Rockefeller University, New York, NY, USA
1:34 PM1:34 PM
406 - Targeting the HIV-1 Latent Reservoir With Tat-CRISPR Lipid Nanoparticles
Keely Gliwa
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:38 PM1:38 PM
405 - Bispecific Biologics That Activate Latent HIV-1 Ex Vivo and In Vivo
David D. Ho
Aaron Diamond AIDS Research Center, New York, NY, USA
1:42 PM1:42 PM
407 - Combination Therapy With Tat mRNA and a TLR9 Agonist Delays Post-ATI Rebound in the NHP Model
Takuto Nogimori
National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
1:46 PM1:46 PM
408 - Markedly Reduced Mutability of Networked Epitopes Promotes CTL Clearance of the Latent HIV Reservoir
Fernando B. Senjobe
Harvard Medical School, Boston, MA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Extra Large Challenges in Steatotic Liver Disease
1:30 PM1:30 PM
Session Overview
Mark Sulkowski
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:34 PM1:34 PM
599 - Simple Adiposity Measures Identify MASLD in People With HIV: Results From a US Multicenter Cohort
Kara Wegermann
Duke University School of Medicine, Durham, NC, USA
1:38 PM1:38 PM
600 - Performance of Prediction Scores for Steatotic Liver Disease in Thai PWH on InSTI-Based ART
Napon Hiranburana
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
1:42 PM1:42 PM
598 - Effect of DTG/3TC vs BIC/FTC/TAF on Steatotic Liver Disease: 96-Week Analysis of PASO-DOBLE Trial
Juan Macias
University of Sevilla, Sevilla, Spain
1:46 PM1:46 PM
601 - Longitudinal Associations of Semaglutide With Liver Fibrosis Score in People With HIV
Jimmy Ma
University of Washington, Seattle, WA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
1:30 PM1:30 PM
Session Overview
Suzue Saito
ICAP at Columbia University, New York, NY, USA
1:34 PM1:34 PM
903 - Quantifying Uncertainty in HIV Transmission Risk From Persons With Low-Level Viremia
Michael Martin
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
1:38 PM1:38 PM
890 - Network Bridges to Predict Emerging HIV Transmission Hotspots in North Carolina
Ann Dennis
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:42 PM1:42 PM
894 - Mapping Recent HIV Infections Among MSM in Thailand: Data-Driven Insights for Targeted Prevention
Michael Reid
1:46 PM1:46 PM
922 - Progress Towards HIV Epidemic Control Among Young Key Populations in India
Eshan U. Patel
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
1:30 PM1:30 PM
Session Overview
Ravi Goyal
University of California San Diego, La Jolla, CA, USA
1:34 PM1:34 PM
1077 - Machine Learning and Longitudinal Data to Predict Unsuppressed HIV Viral Load in Rwanda, 2020-2025
Ndinda Christian
Rwanda Biomedical Centre, Kigali, Rwanda
1:38 PM1:38 PM
1076 - Effect of Machine-Learning-Guided Previsit Outreach to Patients at High Risk to Miss HIV Visits
Joseph W. Hogan
Brown University, Providence, RI, USA
1:42 PM1:42 PM
1079 - Sentiment Analysis of WhatsApp Messages to Identify Unrecognized HIV Prevention Needs in Kenya
Jessica Haberer
Massachusetts General Hospital, Boston, MA, USA
1:46 PM1:46 PM
1078 - Measuring Provider Quality of Care in Tanzania Using Large Language Models
Alaa Abdellatif
University of California San Francisco, San Francisco, CA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
30 Years of Viral Suppression: A Biologic Reset?
4:00 PM4:00 PM
26 - HIV Reservoir: Persistence and Expansion Under Long-Term ART
John W. Mellors
University of Pittsburgh, Pittsburgh, PA, USA
4:20 PM4:20 PM
27 - HIV-Specific T-Cell Responses in People With HIV on Long-Term ART
Victor Appay
University of Bordeaux, Bordeaux, France
4:40 PM4:40 PM
28 - Beyond Undetectable: Chronic Inflammation and Multimorbidity in People With HIV on ART
Irini Sereti
National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA
5:00 PM5:00 PM
Questions and Answers
Michael M. Lederman
Case Western Reserve University, Cleveland, OH, USA
FEB24
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
The Long Game: Progress and the Promise of Long-Acting ART for Treatment
4:00 PM4:00 PM
29 - Clinical Trials and New Drugs in the Pipeline
Onyema Ogbuagu
Yale University, New Haven, CT, USA
4:20 PM4:20 PM
30 - Challenges and Solutions to Implementation
Aadia Rana
University of Alabama at Birmingham, Birmingham, AL, USA
4:40 PM4:40 PM
Panel Discussion
Eric S. Daar
University of California Los Angeles, Los Angeles, CA, USA
4:40 PM4:40 PM
Panel Discussion
Gastón Devisich
Fundación Huésped, Buenos Aires, Argentina
4:40 PM4:40 PM
Panel Discussion
Rosie Mngqibisa
Enhancing Care Foundation, Durban, South Africa
FEB24
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Counting and Caring for Transgender and Gender-Diverse Individuals
4:00 PM4:00 PM
31 - Epidemiology
Stefan Baral
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
4:20 PM4:20 PM
32 - Clinical Management
Asa E. Radix
Callen-Lorde Community Health Center, New York, NY, USA
4:40 PM4:40 PM
33 - Community Evidence, System Change: Transgender Leadership in Sustaining HIV Care
Rena Janamnuaysook
Institute of HIV Research and Innovation, Bangkok, Thailand
5:00 PM5:00 PM
Questions and Answers
Jade Ghosn
Assistance Publique – Hôpitaux de Paris, Paris, France
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestLastName 1
Institution 1
Upcoming:
FEB24
8:30 AMto9:30 AMMST
12:00 PMto5:00 PMMST
Tuesday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Tuesday
Nicolas Chomont
Université de Montréal, Montreal, Canada
8:35 AM8:35 AM
24 - GLP-1 Receptor Agonists: Are They a Cure for Everything?
Todd T. Brown
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
9:05 AM9:05 AM
25 - Syphilis and Superbugs: Sexually Transmitted Infections in the Era of HIV Control
Jeanne Marrazzo
Infectious Diseases Society of America, Arlington, VA, USA
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
HIV Reservoirs and Cure Strategies
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
133 - A Posttranscriptional Block Limits HIV Env Expression in Reactivated Cells From PWH on ART
Jonathan Richard
Centre de Recherche du CHUM, Montreal, Canada
10:13 AM10:13 AM
134 - Altered Viral Kinetics at ATI After Dual LS-bNAbs Plus ART: A Preliminary Analysis of RIO Arm B
Julia Edgar
University of Oxford, Oxford, UK
10:21 AM10:21 AM
135 - Autologous Neutralising Antibodies and Effective CD8 T Cells Maintain HIV Postintervention Control
Katie Fisher
Aarhus University, Aarhus, Denmark
10:29 AM10:29 AM
136 - Bacteria-Specific CD4+ T Cells Contribute to HIV Persistence During ART
Armando Espinosa Ortiz
Université de Montréal, Montreal, Canada
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
137 - CD4-Targeted IL-15 Enhanced bNAb Activity and Improved SHIV Control After Treatment Interruption
Jeffrey Murry
Gilead Sciences, Inc, Foster City, CA, USA
11:13 AM11:13 AM
138 - Decoding the Somatic Mutation Landscape in Persisting HIV-1-Infected CD4+ T Clones
Marie Armani-Tourret
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:21 AM11:21 AM
139 - Ibalizumab-Targeted Delivery of Tat mRNA Transactivates Provirus Expression In Vivo
Edward F. Kreider
University of Pennsylvania, Philadelphia, PA, USA
11:29 AM11:29 AM
140 - Immune-Mediated Viral Control With Budigalimab ± Trosunilimab: First Results of Phase II Global RCT
Ana Gabriela Pires Dos Santos
AbbVie, Inc, North Chicago, IL, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Three Battles - One Stage: TB, Hepatitis, and Hepatocellular Cancer
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
141 - Efficacy and Safety of BLV 2 or 10 mg in CHD Including Patients With HIV/HBV: MYR301 Final Results
David Wyles
Denver Health Medical Center, Denver, CO, USA
10:13 AM10:13 AM
142 - Hepatitis B Reactivation/Infection in People With HIV on Tenofovir-Sparing Antiretroviral Therapy
Grace Haser
University of California San Francisco, San Francisco, CA, USA
10:21 AM10:21 AM
143 - Long-Term Outcomes of Liver Transplant Recipients Living With HIV: A Multicenter Case-Control Study
José M. Miró
Hospital Clinic of Barcelona, Barcelona, Spain
10:29 AM10:29 AM
144 - Early Detection of HCC via Active Surveillance in Persons With HIV in Uganda at High Risk
Katuku Jim Aizire
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
145 - One-Month Versus 3-Month Rifapentine-Based Tuberculosis Preventive Therapy in People With HIV
Anchalee Avihingsanon
Thai Red Cross AIDS Research Centre, Bangkok, Thailand
11:13 AM11:13 AM
146 - Twice-Daily Dolutegravir With a 4-Month Rifapentine-Based Regimen for HIV-Associated Tuberculosis
Sean Wasserman
St George's University of London, London, UK
11:21 AM11:21 AM
147 - DOLPHIN-Moms: Pharmacokinetics and HIV Suppression With Once-Daily Dolutegravir and 3HP in Pregnancy
Jyoti S. Mathad
Weill Cornell Medicine, New York, NY, USA
11:29 AM11:29 AM
148 - Safety and Treatment Completion of 1HP Versus 3HP in People With HIV: The One-to-Three Trial
Jayajothi Moodley
The Aurum Institute, Johannesburg, South Africa
11:37 AM11:37 AM
149 - Novel Linezolid Dosing With Bedaquiline, Delamanid, and Clofazimine for Drug-Resistant TB Treatment
Constance A. Benson
University of California San Diego, La Jolla, CA, USA
11:45 AM11:45 AM
Questions and Answers (Part 2)
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Next-Generation HIV Strategies for Children and Adolescents: Breakthroughs in Pediatric HIV Prevention, Treatment, and Care
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
150 - DOLPHIN-KIDS: Phase I/II Trial of Dolutegravir With 3HP for TB Prevention in Children With HIV
Nicole Salazar-Austin
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:13 AM10:13 AM
151 - Empiric Valganciclovir Reduces Mortality in Infants Living With HIV and Severe Pneumonia
Pablo Rojo
Fundación para la Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain
10:21 AM10:21 AM
152 - Viral Control Among Children in Botswana Receiving Combination Broadly Neutralizing Antibodies
Gbolahan Ajibola
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
10:29 AM10:29 AM
153 - Very Early ART Initiation Associated With Sustained Aviremia in Time-to-Rebound Pediatric ATI
Gabriela Z. L. Cromhout
University of KwaZulu-Natal, Durban, South Africa
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
154 - DTG/3TC Is Noninferior to DTG-Based 3-Drug ART in Children With HIV: D3/Penta 21 Week-96 Results
Anna Turkova
MRC Clinical Trials Unit at UCL, London, UK
11:13 AM11:13 AM
155 - Long-Acting Cabotegravir+Rilpivirine in Adolescents: IMPAACT 2017 Week 96 & End-of-Study Results
Aditya Gaur
St Jude Children's Research Hospital, Memphis, TN, USA
11:21 AM11:21 AM
156 - Improved Viral Suppression and Retention: Randomized Trial of an Adolescent Transition Intervention
Brian Zanoni
Emory University, Atlanta, GA, USA
11:29 AM11:29 AM
157 - Immunogenicity of 2- Versus 3-Dose HPV Vaccination by HIV Infection Status in Eswatini
Harriet Nuwagaba-Biribonwoha
ICAP at Columbia University, New York, NY, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
We Thought You'd Never Ask: Improving HIV Screening and Testing
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
158 - Cluster-Randomized Stepped-Wedge Trial of HIV Rapid Testing and Risk Assessment in Primary Care
Maria Jesus Perez Elias
Ramon y Cajal Hospital, Madrid, Spain
10:13 AM10:13 AM
159 - Enhanced Opt-Out HIV Screening & Linkage to Care for 216K Patients at 13 Community Health Centers
Timothy Long MD
Health Choice Network, Miami, FL, USA
10:21 AM10:21 AM
160 - Electronic Health Record-Driven Universal HIV Screening and Missed Opportunities in Southeastern US
David E. Hudon
Prisma Health, Greenville, SC, USA
10:29 AM10:29 AM
161 - Using Machine Learning to Optimize HIV Risk Prediction and Case Identification in Eastern Kenya
Peter Kyalo
Center for International Health, Education and Biosecurity (CIHEB) Kenya, Nairobi, Kenya
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
162 - Global Analysis of HIV Oral PrEP-to-Need Ratios (PnR) in 2025
Andrew Hill
University of Liverpool, Liverpool, UK
11:13 AM11:13 AM
163 - The Impact of SEARCH Community Precision Health on HIV Incidence in Rural Kenya and Uganda
Gabriel Chamie
University of California San Francisco, San Francisco, CA, USA
11:21 AM11:21 AM
164 - Urine Tenofovir and POC Viral Load Testing After ART Start: Week 72 Outcomes of STREAM-HIV Trial
Paul K. Drain
University of Washington, Seattle, WA, USA
11:29 AM11:29 AM
165 - Evaluating the Viability of Self-Collected Blood for Remotely Testing HIV Suppression Among MSM
Jeffrey Johnson
Centers for Disease Control and Prevention, Atlanta, GA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Targeting the HIV Reservoir: Novel Cure Strategies
1:30 PM1:30 PM
Session Overview
Marina Caskey
The Rockefeller University, New York, NY, USA
1:34 PM1:34 PM
406 - Targeting the HIV-1 Latent Reservoir With Tat-CRISPR Lipid Nanoparticles
Keely Gliwa
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:38 PM1:38 PM
405 - Bispecific Biologics That Activate Latent HIV-1 Ex Vivo and In Vivo
David D. Ho
Aaron Diamond AIDS Research Center, New York, NY, USA
1:42 PM1:42 PM
407 - Combination Therapy With Tat mRNA and a TLR9 Agonist Delays Post-ATI Rebound in the NHP Model
Takuto Nogimori
National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
1:46 PM1:46 PM
408 - Markedly Reduced Mutability of Networked Epitopes Promotes CTL Clearance of the Latent HIV Reservoir
Fernando B. Senjobe
Harvard Medical School, Boston, MA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Extra Large Challenges in Steatotic Liver Disease
1:30 PM1:30 PM
Session Overview
Mark Sulkowski
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:34 PM1:34 PM
599 - Simple Adiposity Measures Identify MASLD in People With HIV: Results From a US Multicenter Cohort
Kara Wegermann
Duke University School of Medicine, Durham, NC, USA
1:38 PM1:38 PM
600 - Performance of Prediction Scores for Steatotic Liver Disease in Thai PWH on InSTI-Based ART
Napon Hiranburana
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
1:42 PM1:42 PM
598 - Effect of DTG/3TC vs BIC/FTC/TAF on Steatotic Liver Disease: 96-Week Analysis of PASO-DOBLE Trial
Juan Macias
University of Sevilla, Sevilla, Spain
1:46 PM1:46 PM
601 - Longitudinal Associations of Semaglutide With Liver Fibrosis Score in People With HIV
Jimmy Ma
University of Washington, Seattle, WA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Precision Comes to Public Health
1:30 PM1:30 PM
Session Overview
Suzue Saito
ICAP at Columbia University, New York, NY, USA
1:34 PM1:34 PM
903 - Quantifying Uncertainty in HIV Transmission Risk From Persons With Low-Level Viremia
Michael Martin
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
1:38 PM1:38 PM
890 - Network Bridges to Predict Emerging HIV Transmission Hotspots in North Carolina
Ann Dennis
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:42 PM1:42 PM
894 - Mapping Recent HIV Infections Among MSM in Thailand: Data-Driven Insights for Targeted Prevention
Michael Reid
1:46 PM1:46 PM
922 - Progress Towards HIV Epidemic Control Among Young Key Populations in India
Eshan U. Patel
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Machines, Models, and Messages
1:30 PM1:30 PM
Session Overview
Ravi Goyal
University of California San Diego, La Jolla, CA, USA
1:34 PM1:34 PM
1077 - Machine Learning and Longitudinal Data to Predict Unsuppressed HIV Viral Load in Rwanda, 2020-2025
Ndinda Christian
Rwanda Biomedical Centre, Kigali, Rwanda
1:38 PM1:38 PM
1076 - Effect of Machine-Learning-Guided Previsit Outreach to Patients at High Risk to Miss HIV Visits
Joseph W. Hogan
Brown University, Providence, RI, USA
1:42 PM1:42 PM
1079 - Sentiment Analysis of WhatsApp Messages to Identify Unrecognized HIV Prevention Needs in Kenya
Jessica Haberer
Massachusetts General Hospital, Boston, MA, USA
1:46 PM1:46 PM
1078 - Measuring Provider Quality of Care in Tanzania Using Large Language Models
Alaa Abdellatif
University of California San Francisco, San Francisco, CA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
30 Years of Viral Suppression: A Biologic Reset?
4:00 PM4:00 PM
26 - HIV Reservoir: Persistence and Expansion Under Long-Term ART
John W. Mellors
University of Pittsburgh, Pittsburgh, PA, USA
4:20 PM4:20 PM
27 - HIV-Specific T-Cell Responses in People With HIV on Long-Term ART
Victor Appay
University of Bordeaux, Bordeaux, France
4:40 PM4:40 PM
28 - Beyond Undetectable: Chronic Inflammation and Multimorbidity in People With HIV on ART
Irini Sereti
National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA
5:00 PM5:00 PM
Questions and Answers
Michael M. Lederman
Case Western Reserve University, Cleveland, OH, USA
FEB24
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
The Long Game: Progress and the Promise of Long-Acting ART for Treatment
4:00 PM4:00 PM
29 - Clinical Trials and New Drugs in the Pipeline
Onyema Ogbuagu
Yale University, New Haven, CT, USA
4:20 PM4:20 PM
30 - Challenges and Solutions to Implementation
Aadia Rana
University of Alabama at Birmingham, Birmingham, AL, USA
4:40 PM4:40 PM
Panel Discussion
Eric S. Daar
University of California Los Angeles, Los Angeles, CA, USA
4:40 PM4:40 PM
Panel Discussion
Gastón Devisich
Fundación Huésped, Buenos Aires, Argentina
4:40 PM4:40 PM
Panel Discussion
Rosie Mngqibisa
Enhancing Care Foundation, Durban, South Africa
FEB24
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Counting and Caring for Transgender and Gender-Diverse Individuals
4:00 PM4:00 PM
31 - Epidemiology
Stefan Baral
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
4:20 PM4:20 PM
32 - Clinical Management
Asa E. Radix
Callen-Lorde Community Health Center, New York, NY, USA
4:40 PM4:40 PM
33 - Community Evidence, System Change: Transgender Leadership in Sustaining HIV Care
Rena Janamnuaysook
Institute of HIV Research and Innovation, Bangkok, Thailand
5:00 PM5:00 PM
Questions and Answers
Jade Ghosn
Assistance Publique – Hôpitaux de Paris, Paris, France
FEB24
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 5
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestLastName 1
Institution 1
Previous:
FEB24
8:30 AMto9:30 AMMST
12:00 PMto5:00 PMMST
Tuesday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Tuesday
Nicolas Chomont
Université de Montréal, Montreal, Canada
8:35 AM8:35 AM
24 - GLP-1 Receptor Agonists: Are They a Cure for Everything?
Todd T. Brown
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
9:05 AM9:05 AM
25 - Syphilis and Superbugs: Sexually Transmitted Infections in the Era of HIV Control
Jeanne Marrazzo
Infectious Diseases Society of America, Arlington, VA, USA
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
HIV Reservoirs and Cure Strategies
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
133 - A Posttranscriptional Block Limits HIV Env Expression in Reactivated Cells From PWH on ART
Jonathan Richard
Centre de Recherche du CHUM, Montreal, Canada
10:13 AM10:13 AM
134 - Altered Viral Kinetics at ATI After Dual LS-bNAbs Plus ART: A Preliminary Analysis of RIO Arm B
Julia Edgar
University of Oxford, Oxford, UK
10:21 AM10:21 AM
135 - Autologous Neutralising Antibodies and Effective CD8 T Cells Maintain HIV Postintervention Control
Katie Fisher
Aarhus University, Aarhus, Denmark
10:29 AM10:29 AM
136 - Bacteria-Specific CD4+ T Cells Contribute to HIV Persistence During ART
Armando Espinosa Ortiz
Université de Montréal, Montreal, Canada
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
137 - CD4-Targeted IL-15 Enhanced bNAb Activity and Improved SHIV Control After Treatment Interruption
Jeffrey Murry
Gilead Sciences, Inc, Foster City, CA, USA
11:13 AM11:13 AM
138 - Decoding the Somatic Mutation Landscape in Persisting HIV-1-Infected CD4+ T Clones
Marie Armani-Tourret
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:21 AM11:21 AM
139 - Ibalizumab-Targeted Delivery of Tat mRNA Transactivates Provirus Expression In Vivo
Edward F. Kreider
University of Pennsylvania, Philadelphia, PA, USA
11:29 AM11:29 AM
140 - Immune-Mediated Viral Control With Budigalimab ± Trosunilimab: First Results of Phase II Global RCT
Ana Gabriela Pires Dos Santos
AbbVie, Inc, North Chicago, IL, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Three Battles - One Stage: TB, Hepatitis, and Hepatocellular Cancer
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
141 - Efficacy and Safety of BLV 2 or 10 mg in CHD Including Patients With HIV/HBV: MYR301 Final Results
David Wyles
Denver Health Medical Center, Denver, CO, USA
10:13 AM10:13 AM
142 - Hepatitis B Reactivation/Infection in People With HIV on Tenofovir-Sparing Antiretroviral Therapy
Grace Haser
University of California San Francisco, San Francisco, CA, USA
10:21 AM10:21 AM
143 - Long-Term Outcomes of Liver Transplant Recipients Living With HIV: A Multicenter Case-Control Study
José M. Miró
Hospital Clinic of Barcelona, Barcelona, Spain
10:29 AM10:29 AM
144 - Early Detection of HCC via Active Surveillance in Persons With HIV in Uganda at High Risk
Katuku Jim Aizire
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
145 - One-Month Versus 3-Month Rifapentine-Based Tuberculosis Preventive Therapy in People With HIV
Anchalee Avihingsanon
Thai Red Cross AIDS Research Centre, Bangkok, Thailand
11:13 AM11:13 AM
146 - Twice-Daily Dolutegravir With a 4-Month Rifapentine-Based Regimen for HIV-Associated Tuberculosis
Sean Wasserman
St George's University of London, London, UK
11:21 AM11:21 AM
147 - DOLPHIN-Moms: Pharmacokinetics and HIV Suppression With Once-Daily Dolutegravir and 3HP in Pregnancy
Jyoti S. Mathad
Weill Cornell Medicine, New York, NY, USA
11:29 AM11:29 AM
148 - Safety and Treatment Completion of 1HP Versus 3HP in People With HIV: The One-to-Three Trial
Jayajothi Moodley
The Aurum Institute, Johannesburg, South Africa
11:37 AM11:37 AM
149 - Novel Linezolid Dosing With Bedaquiline, Delamanid, and Clofazimine for Drug-Resistant TB Treatment
Constance A. Benson
University of California San Diego, La Jolla, CA, USA
11:45 AM11:45 AM
Questions and Answers (Part 2)
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Next-Generation HIV Strategies for Children and Adolescents: Breakthroughs in Pediatric HIV Prevention, Treatment, and Care
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
150 - DOLPHIN-KIDS: Phase I/II Trial of Dolutegravir With 3HP for TB Prevention in Children With HIV
Nicole Salazar-Austin
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:13 AM10:13 AM
151 - Empiric Valganciclovir Reduces Mortality in Infants Living With HIV and Severe Pneumonia
Pablo Rojo
Fundación para la Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain
10:21 AM10:21 AM
152 - Viral Control Among Children in Botswana Receiving Combination Broadly Neutralizing Antibodies
Gbolahan Ajibola
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
10:29 AM10:29 AM
153 - Very Early ART Initiation Associated With Sustained Aviremia in Time-to-Rebound Pediatric ATI
Gabriela Z. L. Cromhout
University of KwaZulu-Natal, Durban, South Africa
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
154 - DTG/3TC Is Noninferior to DTG-Based 3-Drug ART in Children With HIV: D3/Penta 21 Week-96 Results
Anna Turkova
MRC Clinical Trials Unit at UCL, London, UK
11:13 AM11:13 AM
155 - Long-Acting Cabotegravir+Rilpivirine in Adolescents: IMPAACT 2017 Week 96 & End-of-Study Results
Aditya Gaur
St Jude Children's Research Hospital, Memphis, TN, USA
11:21 AM11:21 AM
156 - Improved Viral Suppression and Retention: Randomized Trial of an Adolescent Transition Intervention
Brian Zanoni
Emory University, Atlanta, GA, USA
11:29 AM11:29 AM
157 - Immunogenicity of 2- Versus 3-Dose HPV Vaccination by HIV Infection Status in Eswatini
Harriet Nuwagaba-Biribonwoha
ICAP at Columbia University, New York, NY, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB24
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
We Thought You'd Never Ask: Improving HIV Screening and Testing
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
158 - Cluster-Randomized Stepped-Wedge Trial of HIV Rapid Testing and Risk Assessment in Primary Care
Maria Jesus Perez Elias
Ramon y Cajal Hospital, Madrid, Spain
10:13 AM10:13 AM
159 - Enhanced Opt-Out HIV Screening & Linkage to Care for 216K Patients at 13 Community Health Centers
Timothy Long MD
Health Choice Network, Miami, FL, USA
10:21 AM10:21 AM
160 - Electronic Health Record-Driven Universal HIV Screening and Missed Opportunities in Southeastern US
David E. Hudon
Prisma Health, Greenville, SC, USA
10:29 AM10:29 AM
161 - Using Machine Learning to Optimize HIV Risk Prediction and Case Identification in Eastern Kenya
Peter Kyalo
Center for International Health, Education and Biosecurity (CIHEB) Kenya, Nairobi, Kenya
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
162 - Global Analysis of HIV Oral PrEP-to-Need Ratios (PnR) in 2025
Andrew Hill
University of Liverpool, Liverpool, UK
11:13 AM11:13 AM
163 - The Impact of SEARCH Community Precision Health on HIV Incidence in Rural Kenya and Uganda
Gabriel Chamie
University of California San Francisco, San Francisco, CA, USA
11:21 AM11:21 AM
164 - Urine Tenofovir and POC Viral Load Testing After ART Start: Week 72 Outcomes of STREAM-HIV Trial
Paul K. Drain
University of Washington, Seattle, WA, USA
11:29 AM11:29 AM
165 - Evaluating the Viability of Self-Collected Blood for Remotely Testing HIV Suppression Among MSM
Jeffrey Johnson
Centers for Disease Control and Prevention, Atlanta, GA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Targeting the HIV Reservoir: Novel Cure Strategies
1:30 PM1:30 PM
Session Overview
Marina Caskey
The Rockefeller University, New York, NY, USA
1:34 PM1:34 PM
406 - Targeting the HIV-1 Latent Reservoir With Tat-CRISPR Lipid Nanoparticles
Keely Gliwa
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:38 PM1:38 PM
405 - Bispecific Biologics That Activate Latent HIV-1 Ex Vivo and In Vivo
David D. Ho
Aaron Diamond AIDS Research Center, New York, NY, USA
1:42 PM1:42 PM
407 - Combination Therapy With Tat mRNA and a TLR9 Agonist Delays Post-ATI Rebound in the NHP Model
Takuto Nogimori
National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
1:46 PM1:46 PM
408 - Markedly Reduced Mutability of Networked Epitopes Promotes CTL Clearance of the Latent HIV Reservoir
Fernando B. Senjobe
Harvard Medical School, Boston, MA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Extra Large Challenges in Steatotic Liver Disease
1:30 PM1:30 PM
Session Overview
Mark Sulkowski
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:34 PM1:34 PM
599 - Simple Adiposity Measures Identify MASLD in People With HIV: Results From a US Multicenter Cohort
Kara Wegermann
Duke University School of Medicine, Durham, NC, USA
1:38 PM1:38 PM
600 - Performance of Prediction Scores for Steatotic Liver Disease in Thai PWH on InSTI-Based ART
Napon Hiranburana
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
1:42 PM1:42 PM
598 - Effect of DTG/3TC vs BIC/FTC/TAF on Steatotic Liver Disease: 96-Week Analysis of PASO-DOBLE Trial
Juan Macias
University of Sevilla, Sevilla, Spain
1:46 PM1:46 PM
601 - Longitudinal Associations of Semaglutide With Liver Fibrosis Score in People With HIV
Jimmy Ma
University of Washington, Seattle, WA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Precision Comes to Public Health
1:30 PM1:30 PM
Session Overview
Suzue Saito
ICAP at Columbia University, New York, NY, USA
1:34 PM1:34 PM
903 - Quantifying Uncertainty in HIV Transmission Risk From Persons With Low-Level Viremia
Michael Martin
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
1:38 PM1:38 PM
890 - Network Bridges to Predict Emerging HIV Transmission Hotspots in North Carolina
Ann Dennis
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:42 PM1:42 PM
894 - Mapping Recent HIV Infections Among MSM in Thailand: Data-Driven Insights for Targeted Prevention
Michael Reid
1:46 PM1:46 PM
922 - Progress Towards HIV Epidemic Control Among Young Key Populations in India
Eshan U. Patel
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Machines, Models, and Messages
1:30 PM1:30 PM
Session Overview
Ravi Goyal
University of California San Diego, La Jolla, CA, USA
1:34 PM1:34 PM
1077 - Machine Learning and Longitudinal Data to Predict Unsuppressed HIV Viral Load in Rwanda, 2020-2025
Ndinda Christian
Rwanda Biomedical Centre, Kigali, Rwanda
1:38 PM1:38 PM
1076 - Effect of Machine-Learning-Guided Previsit Outreach to Patients at High Risk to Miss HIV Visits
Joseph W. Hogan
Brown University, Providence, RI, USA
1:42 PM1:42 PM
1079 - Sentiment Analysis of WhatsApp Messages to Identify Unrecognized HIV Prevention Needs in Kenya
Jessica Haberer
Massachusetts General Hospital, Boston, MA, USA
1:46 PM1:46 PM
1078 - Measuring Provider Quality of Care in Tanzania Using Large Language Models
Alaa Abdellatif
University of California San Francisco, San Francisco, CA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB24
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
30 Years of Viral Suppression: A Biologic Reset?
4:00 PM4:00 PM
26 - HIV Reservoir: Persistence and Expansion Under Long-Term ART
John W. Mellors
University of Pittsburgh, Pittsburgh, PA, USA
4:20 PM4:20 PM
27 - HIV-Specific T-Cell Responses in People With HIV on Long-Term ART
Victor Appay
University of Bordeaux, Bordeaux, France
4:40 PM4:40 PM
28 - Beyond Undetectable: Chronic Inflammation and Multimorbidity in People With HIV on ART
Irini Sereti
National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA
5:00 PM5:00 PM
Questions and Answers
Michael M. Lederman
Case Western Reserve University, Cleveland, OH, USA
FEB24
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
The Long Game: Progress and the Promise of Long-Acting ART for Treatment
4:00 PM4:00 PM
29 - Clinical Trials and New Drugs in the Pipeline
Onyema Ogbuagu
Yale University, New Haven, CT, USA
4:20 PM4:20 PM
30 - Challenges and Solutions to Implementation
Aadia Rana
University of Alabama at Birmingham, Birmingham, AL, USA
4:40 PM4:40 PM
Panel Discussion
Eric S. Daar
University of California Los Angeles, Los Angeles, CA, USA
4:40 PM4:40 PM
Panel Discussion
Gastón Devisich
Fundación Huésped, Buenos Aires, Argentina
4:40 PM4:40 PM
Panel Discussion
Rosie Mngqibisa
Enhancing Care Foundation, Durban, South Africa
FEB24
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Counting and Caring for Transgender and Gender-Diverse Individuals
4:00 PM4:00 PM
31 - Epidemiology
Stefan Baral
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
4:20 PM4:20 PM
32 - Clinical Management
Asa E. Radix
Callen-Lorde Community Health Center, New York, NY, USA
4:40 PM4:40 PM
33 - Community Evidence, System Change: Transgender Leadership in Sustaining HIV Care
Rena Janamnuaysook
Institute of HIV Research and Innovation, Bangkok, Thailand
5:00 PM5:00 PM
Questions and Answers
Jade Ghosn
Assistance Publique – Hôpitaux de Paris, Paris, France
FEB24
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 5
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestLastName 1
Institution 1
